Trial Profile
Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer: a Prospective Single-center Multi-arm Open-label Randomized Phase II Study
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Aug 2023
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Clostridium butyricum M588 (Primary) ; Envafolimab (Primary) ; Oxaliplatin (Primary)
- Indications Adenocarcinoma; Colon cancer
- Focus Therapeutic Use
- Acronyms ICONIC
- 06 Aug 2023 Planned End Date changed from 1 Jun 2025 to 1 Aug 2030.
- 06 Aug 2023 Planned primary completion date changed from 1 Jun 2025 to 1 Aug 2025.
- 06 Aug 2023 Status changed from not yet recruiting to recruiting.